Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 8/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336721 | 0.87 | LMNA (0.42) | PDE7ASMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL5833149 | 0.77 | PDE7A (0.56) | PDE7ASMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL28351783 | 0.77 | LMNA (0.46) | PDE7ASMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL3055047 | 0.77 | GPR35 (0.39) | PDE7ASMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL3838786 | 0.77 | PDE7A (0.35) | PDE7ASMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL8973300 | 0.74 | ALDH1A1 (0.49) | SMN1; SMN2LMNAALDH1A1MAPTKMT2A | |
| SCHEMBL4368894 | 0.73 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1KMT2APKMCA12 | |
| SCHEMBL9635033 | 0.73 | APOBEC3G (0.55) | SMN1; SMN2ALDH1A1MAPTAPOBEC3GKMT2A | |
| SCHEMBL2461047 | 0.73 | POLB (0.59) | SMN1; SMN2LMNAALDH1A1MAPTKMT2A | |
| SCHEMBL31163274 | 0.73 | POLB (0.59) | SMN1; SMN2LMNAALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431699-B2 | Method for manufacture of 2-oxoimidazolidines | Vertichem Corporation (CA) | 2013-04-30 | — | — | US | disclosed |
| WO-2010099518-A2 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | THESIS CHEMISTRY, LLC (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099029-A1 | EPOXY COMPOSITIONS WITH IMPROVED MECHANICAL PERFORMANCE | CYTEC TECHNOLOGY CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100222461-A1 | EPOXY COMPOSITIONS WITH IMPROVED MECHANICAL PERFORMANCE | CYTEC TECHNOLOGY CORP. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | THESIS CHEMISTRY, LLC (US) | 2010-09-02 | — | — | US | disclosed |
| US-6627714-B2 | Copolymerizing ethylene and dicyclopentadiene or tricyclopentadiene, and cyclic olefin in presence of metallocene catalyst to produce copolymer | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20020058767-A1 | Method for producing an olefin type copolymer having a cyclic structure | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1205497-A2 | Method for producing an olefin type copolymer having a cyclic structure | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | ODC1, CBR3, CBR1 | PDE7A 711/4885SMN1; SMN2 4607/4885LMNA 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.